RaySearch Laboratories AB (27R) Stock Price & Analysis
27R Stock Chart & Stats
- Day’s Range
- EUR 18.09 - EUR 18.09
- 52-Week Range
- EUR 14.73 - EUR 23.20
- Previous Close
- EUR 17.88
- Volume
- N/A
- Average Volume (3M)
- 21
- Market Cap
- EUR 634.29M
- Enterprise Value
- EUR 7.68B
- Total Cash (Recent Filing)
- EUR 213.10M
- Total Debt (Recent Filing)
- EUR 359.20M
- Price to Earnings (P/E)
- 32.7
- Beta
- 1.15
- Next Earnings
- Nov 03, 2026 (Est.)
- EPS Estimate
- 0.22
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 1.62%
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation
Robust operating and free cash flow gives RaySearch capacity to fund product development, customer implementations and market expansion internally. Strong cash conversion also improves resilience through uneven license cycles, while reducing dependence on external financing for ongoing strategic investment.
Growing Recurring Support Base
A substantial and growing support contribution provides a more durable revenue foundation than new license sales alone. Continued customer payments for updates and technical support can improve visibility, reinforce retention, and help cushion volatility in larger hospital purchasing cycles.
Established Global Market Position
A broad installed base across many countries indicates meaningful clinical adoption and accumulated market credibility. Scale can support recurring service revenue, generate reference value in future hospital tenders, and strengthen RaySearch's position as its oncology software platform expands.
Bears Say
Recent Revenue And Margin Contraction
The weak quarter shows that RaySearch's earnings remain exposed to timing and volume fluctuations in license-driven sales. Lower revenue and margin reduce operating leverage, and repeated softness would make it harder to sustain profitability while continuing investment in products and market development.
U.S. Procurement Execution Risk
Delays in an important market can defer license revenue and leave hospital projects exposed to budget and reimbursement decisions outside RaySearch's control. This raises execution risk because management's 2026 margin plan depends on a strong recovery and conversion of delayed opportunities.
Limited Subscription Adoption
A predominantly upfront CapEx model makes revenue recognition more dependent on the timing of large hospital purchases and project approvals. Limited subscription adoption reduces near-term recurring smoothing, leaving results more vulnerable to procurement delays and uneven quarterly demand.
RaySearch Laboratories AB News
27R FAQ
What was RaySearch Laboratories AB’s price range in the past 12 months?
What is RaySearch Laboratories AB’s market cap?
When is RaySearch Laboratories AB’s upcoming earnings report date?
How were RaySearch Laboratories AB’s earnings last quarter?
Is RaySearch Laboratories AB overvalued?
Does RaySearch Laboratories AB pay dividends?
What is RaySearch Laboratories AB’s EPS estimate?
How many shares outstanding does RaySearch Laboratories AB have?
What happened to RaySearch Laboratories AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of RaySearch Laboratories AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
RaySearch Laboratories AB
RaySearch Laboratories AB (publ) is a global medical technology company dedicated to developing cutting-edge software solutions for cancer treatment. Its principal offering, RayStation, is a sophisticated treatment planning system that supports a vast range of clinical activities. These capabilities include automated planning, adaptive therapy, multi-criteria optimization, rapid and accurate dose calculations, OAR dose reduction, robustness modeling, machine learning integration, and support for advanced radiation modalities such as VMAT, IMRT, 3D-CRT, virtual simulation, electron beam therapy, tomotherapy, stereotactic treatments, proton therapy, carbon ion therapy, and boron neutron capture therapy. The company also offers RayPlan, another treatment planning system specifically designed for various radiation therapy methods including 3D-CRT, IMRT, VMAT, tomotherapy, and electron beam radiation therapy. For managing oncology workflows, RayCare serves as a dedicated information system. Additionally, RaySearch provides RayCommand, a flexible treatment control system compatible with diverse hardware and designed to manage advanced functionalities of treatment machines and software. To leverage patient data, its cloud-based oncology analytics system, RayIntelligence, converts raw information into valuable insights. RaySearch Laboratories AB (publ) further provides training courses for its products and is headquartered in Stockholm, Sweden.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Johan Lof
- Employees
- 464
- Website
- www.raysearchlabs.com
- Address
- Eugeniavägen 18C, Stockholm, AB, 113 68, SE
RaySearch Laboratories AB (27R) Earnings & Revenues
27R Company Deck
27R Earnings Call
Earnings Call SentimentNeutral
The call reported a clearly disappointing Q2 with meaningful declines in license and hardware sales (license -18%, hardware -38%, net sales -11%) and a compressed EBIT margin (10%). However, several positive indicators offset the weakness: order intake grew 23%, backlog remains robust at SEK 1.691 billion (SEK 670 million expected to convert within 12 months), LTM organic growth was 9% with a 22% LTM EBIT margin, notable strategic wins (Dana-Farber and other U.S. orders recovered in early Q3), clinical milestones (online adaptive treatments on TrueBeam), product releases and strengthened proton expertise, improved cash flow (Q2 free cash flow SEK 50 million) and active share repurchases. Management believes a strong H2 can restore the year’s financial trajectory but execution risk remains. Overall, the positive backlog, early Q3 order recoveries and recurring revenue stability balance the quarter’s operational weaknesses and timing risks.
View all DE:27R earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 3 | 4 |
| Technical Analysis | 2 | 3 | 4 |
| Moving Averages | 12 | 0 | 0 |
